Skip to main navigation Skip to search Skip to main content

Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: a randomised, double-blind, parallel-group, non-inferiority phase 3 trial

  • Won Seog Kim
  • , Christian Buske
  • , Michinori Ogura
  • , Wojciech Jurczak
  • , Juan Manuel Sancho
  • , Edvard Zhavrid
  • , Jin Seok Kim
  • , José Ángel Hernández-Rivas
  • , Aliaksandr Prokharau
  • , Mariana Vasilica
  • , Rajinish Nagarkar
  • , Dzhelil Osmanov
  • , Larry W. Kwak
  • , Sang Joon Lee
  • , Sung Young Lee
  • , Yun Ju Bae
  • , Bertrand Coiffier
  • Sungkyunkwan University
  • Ulm University
  • Tokai Central Hospital
  • Jagiellonian University in Kraków
  • Generalitat de Catalunya
  • N N Alexandrov Republican Scientific and Practical Centre of Oncology and Medical Radiology
  • Yonsei University
  • Hospital Universitario Infanta Leonor
  • Minsk City Clinical Oncology Dispensary
  • Fundeni Clinical Institute
  • Curie Manavata Cancer Centre
  • N N Blokhin Russian Cancer Research Centre
  • City of Hope National Med Center
  • Celltrion
  • Hospices civils de Lyon

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: a randomised, double-blind, parallel-group, non-inferiority phase 3 trial'. Together they form a unique fingerprint.
Sort by

Pharmacology, Toxicology and Pharmaceutical Science

Biochemistry, Genetics and Molecular Biology